Stachybotrys (Black Mold) and Allergy Shots: Myth vs Evidence
Stachybotrys chartarum allergy shots (SCIT) do not exist as an evidence-based treatment — no controlled trial has been conducted and the AAAAI/ACAAI Practice Parameter does not recommend it. Remediation and source water control are the primary clinical interventions for black mold exposure. CDC's May 2024 position states the association of S.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Stachybotrysis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Stachybotrys Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to stachybotrys — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of stachybotrys allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of stachybotrys immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of stachybotrys extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for stachybotrys allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing stachybotrys extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription stachybotrys immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat stachybotrys allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Stachybotrys?
The biology, taxonomy, and clinical fingerprint of Stachybotrys — the foundation of how SCIT targets it.
Stachybotrys chartarum — dark/black colonies with slimy spore masses held by polysaccharide matrix. Spores do NOT readily aerosolize — studies failed to collect airborne Stachybotrys even in buildings with extensive growth (Brasel TL et al., Appl Environ Microbiol 2005).
- Scientific name
- Stachybotrys chartarum
- Family
- StachybotryaceaeHypocreales, Sordariomycetes, Ascomycota
- Type
- Indoor water-damage indicator mold — slow-growing, requires very high moisture
- Native to
- Cosmopolitan — cellulose-rich water-damaged materials; NOT a common outdoor mold
- Allergen proteins
- Sta c 3 — only identified major allergen; IgE found in only 9.4% of healthy individuals (Barnes C et al., Ann Allergy Asthma Immunol 2002)IgG found in 49.2% of healthy individuals — widespread exposure but limited IgE responseMycotoxins (NOT allergens): satratoxins (Chemotype S — ~1/3 of isolates), atranones (Chemotype A)
- Particle size
- Conidia 7–12 × 4–6 µm produced in slimy masses — do NOT readily become airborne under normal conditions
- Avoidance difficulty
- Moderate
How Stachybotrys Allergy Presents
Symptoms by body system — useful for distinguishing Stachybotrys sensitivity from overlapping allergies and infections.
Respiratory
- Upper respiratory symptoms in water-damaged-building occupants — cough, nasal congestion, wheeze (caused by broad mold exposure, not specifically S. chartarum toxins per IOM 2004)
- Asthma exacerbation in asthmatics living in water-damaged buildings (same broad-mold-exposure mechanism)
- Hypersensitivity pneumonitis — documented from various mold exposures in buildings; Stachybotrys-specific HP is rare and not well-characterized
- Rhinitis in the minority of patients with IgE sensitization (Sta c 3 positivity in 9.4% of exposed individuals)
Ocular
- Allergic conjunctivitis in the minority with documented Stachybotrys IgE sensitization
- Eye irritation in water-damaged-building occupants — often non-IgE-mediated, related to dust and VOC exposure
- Periorbital edema in patients with confirmed IgE-mediated mold allergy
Dermal
- Skin irritation reported by occupants of water-damaged buildings — mechanism is often non-immunologic (VOCs, mycotoxins at surfaces)
- Contact urticaria in the rare patient with confirmed Sta c 3 IgE sensitization
- Rash symptoms frequently reported by 'black mold illness' patients — evidence base for specific Stachybotrys causation is limited per CDC and IOM reviews
Systemic
- The 'toxic black mold syndrome' (fatigue, cognitive fog, systemic illness) attributed to Stachybotrys in lay media is not confirmed by IOM 2004 or CDC 2024 evidence review
- Mycotoxin exposure (satratoxins): documented toxic effects require high direct exposures; building airborne mycotoxin levels are typically far below toxic thresholds per IOM 2004
- Anaphylaxis not documented from inhaled Stachybotrys; theoretical risk in high-IgE sensitized patients
When someone comes in after finding black mold in their home convinced it's causing every symptom they have, my job is two things: validate that water-damaged buildings do cause real respiratory symptoms, and be honest that the mechanism is broad mold and mycotoxin exposure — not a specific Stachybotrys toxin syndrome the way the internet describes it. There is no Stachybotrys allergy shot, and I wouldn't prescribe one even if I could. The treatment is fixing the moisture problem.
Where Stachybotrys Triggers Year-Round
Stachybotrys is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundYear-round indoor — Stachybotrys grows continuously as long as the moisture source persists; spores are not seasonal· Perennial in affected buildings; growth continues until water source is eliminated and contaminated materials removed
US Exposure Map
0 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Stachybotrys Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Stachybotrys has a poorly characterized allergen profile; Sta c 3 has no confirmed cross-reactive allergens, and cross-reactivity data relies on pan-fungal carbohydrate epitopes rather than protein-level homology.
Co-occurring water-damage Sordariomycetes; both cellulose-degrading molds in chronically wet buildings; limited characterized component overlap
Both Hypocreales water-damage molds; shared building-remediation context; minor extract-level overlap
Extract-level overlap in mold-mix panels; no individual component homology established for Stachybotrys
Both pigmented molds in atopic panels; minimal characterized cross-reactivity
Is SCIT Right for Your Stachybotrys Allergy?
This five-question assessment focuses on what actually matters for someone who has found black mold — helping prioritize the right next steps over SCIT, which is not an option.
Do you have confirmed Stachybotrys or black mold identified in your home or workplace?
The Stachybotrys SCIT Protocol
Stachybotrys SCIT does not exist. The clinical management protocol for patients with Stachybotrys exposure follows the EPA remediation framework, not an immunotherapy protocol.
Identify and stop the water source — roof leak, plumbing failure, flood. Stachybotrys requires water activity above 0.94 (serious water damage), meaning it will not grow without an active moisture source. Stopping the water source is the single most important intervention. Patients with asthma or lung disease should not enter water-damaged buildings during this phase.
EPA threshold for professional remediation: mold growth above 10 square feet. Stachybotrys-containing porous materials (drywall, ceiling tiles, carpet, wood) must be removed and discarded — not cleaned, not painted over. N95 respirator, gloves, and goggles required for any remediation. Professional services recommended for Stachybotrys due to mycotoxin concerns. Do not use bleach on porous surfaces — it does not penetrate the substrate.
If respiratory symptoms persist after professional remediation, IgE testing for the four molds with SCIT extracts — Alternaria, Cladosporium, Aspergillus, Penicillium — is more clinically useful than Stachybotrys IgE alone. These molds frequently co-occur in water-damaged buildings and have immunotherapy options. A board-certified allergist can prescribe SCIT for whichever co-positive molds meet the clinical threshold for treatment.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Stachybotrys SCIT
There is no efficacy data for Stachybotrys SCIT. The evidence that exists for Stachybotrys-related health management is for environmental remediation and broader mold-allergen immunotherapy for co-positive species.
- Professional remediation — symptom improvement in water-damaged-building occupants55%IOM 2004 Damp Indoor Spaces and Health — sufficient evidence that remediation reduces upper respiratory symptoms, cough, wheeze, and asthma exacerbations in mold-sensitized occupants
- Alternaria SCIT combined score reduction at year 3 (co-positive mold with actual evidence)64%Kuna P et al., JACI 2011 — Alternaria, which commonly co-occurs in water-damaged buildings, is the mold with robust RCT evidence
Stachybotrys SCIT has zero efficacy evidence. The interventions with documented outcomes for Stachybotrys-contaminated building occupants are: professional remediation of the moisture source and affected materials per EPA guidelines, followed by IgE testing for co-positive molds with SCIT evidence (Alternaria foremost), and antihistamines plus nasal steroids for ongoing symptom control. Stachybotrys IgE testing is useful for documentation — not for guiding immunotherapy.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Stachybotrys SCIT Side Effects
Stachybotrys SCIT is not prescribed; patient-level side effect data does not exist. The relevant safety information concerns occupant exposure during building remediation, not injection reactions.
Local reactions
1 documented| Reaction | Rate | Severity |
|---|---|---|
Remediation exposure risk — particulate and mycotoxin release during dry-out or disruption Spore counts can increase when Stachybotrys colonies dry out or are disturbed; always use N95, gloves, goggles during cleanup | Rate High if proper PPE not used | Moderate |
Systemic reactions
2 documented| Reaction | Rate | Severity |
|---|---|---|
Asthma exacerbation during building exposure Patients with asthma or lung disease should NOT enter water-damaged buildings during active remediation | Rate Moderate risk in sensitized asthmatics | Moderate |
Mycotoxin-related irritation during high-disturbance remediation Concern is primarily with direct surface contact or inhalation of disturbed heavy growth areas — not typical indoor ambient exposure | Rate Rare — typical building airborne levels far below toxic thresholds (IOM 2004) | Mild |
The primary Stachybotrys safety concern is not SCIT reactions — it is remediation exposure. Stachybotrys spores are normally slimy and not readily airborne, but disturbance during removal can release spores and mycotoxin-containing particles. Professional remediators and occupants re-entering recently remediated spaces should use N95 protection and ensure mechanical ventilation.
SCIT vs Alternatives for Stachybotrys
For Stachybotrys exposure, the evidence-based management hierarchy is clear: remediation first, then allergy testing for co-positive molds with available SCIT extracts. SCIT for Stachybotrys itself does not exist.
| Criterion | Stachybotrys SCIT | Professional RemediationBest | Alternaria SCIT (if co-positive) | Medications |
|---|---|---|---|---|
| Effectiveness | DOES NOT EXIST — not prescribed | Removes the source — IOM 2004 confirms symptom improvement | 63.5% combined score reduction at year 3 (Kuna 2011) | Good symptom control — does not address building exposure |
| 5-yr cost | N/A | Variable — $500 to $15,000+ depending on extent | $3,500–$15,000 over 5 years | $500–$2,000/year |
| Duration | N/A | One-time + ongoing moisture control | 3–5 years | Indefinite while in affected building |
| Convenience | N/A | Professional service — 3–14 days typically | Weekly then monthly clinic visits | Daily pills and sprays |
| Safety | Not applicable | No injection risk; PPE required during work | Standard SCIT safety profile | Generally safe |
| Lasting effect | Unknown | Permanent if moisture source is eliminated | 7–12+ years post-treatment | No disease modification |
Stachybotrys SCIT
Professional RemediationBest
Alternaria SCIT (if co-positive)
Medications
Professional remediation is the only evidence-based primary intervention for Stachybotrys. After remediation, a Curex allergist can order the extended mold IgE panel to identify co-positive molds (Alternaria, Cladosporium, Aspergillus, Penicillium) that do have SCIT extracts — so patients are not left without an immunotherapy pathway just because Stachybotrys itself has no shot. For eligible patients who test positive for co-positive evidence-supported molds, Curex's at-home SCIT program delivers personalized compounded serum with pricing confirmed in a current program quote, one weekly shot at home.
What Stachybotrys SCIT Actually Costs
Stachybotrys IgE testing (ImmunoCAP m227) may be covered under standard lab benefits as part of a mold-allergy panel; its primary use is for documentation in insurance or legal remediation disputes. Professional mold remediation coverage depends on homeowner's insurance policy and cause of water damage. Stachybotrys SCIT is not a billable claim. Curex at-home IgE testing identifies specific stachybotrys sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your stachybotrys allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Stachybotrys SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
The 'toxic black mold' narrative overstates what the science shows. CDC's updated May 2024 position states: 'A possible association between acute idiopathic pulmonary hemorrhage among infants and Stachybotrys chartarum has not been proven.' The Cleveland infant pulmonary hemorrhage cluster of 1993–1996, which initially implicated Stachybotrys, was reviewed by CDC in 2000 and found to have methodological flaws — the association was NOT confirmed. The Institute of Medicine 2004 report ('Damp Indoor Spaces and Health') found sufficient evidence linking indoor mold exposure — any species — with upper respiratory symptoms, cough, wheeze, asthma symptoms, and hypersensitivity pneumonitis in susceptible individuals. However, IOM did not find sufficient evidence for the specific 'toxic black mold syndrome' attributed to Stachybotrys in popular media. Real symptoms from water-damaged buildings are real — but they are caused by broad mold exposure, not specifically by Stachybotrys satratoxins.
Stachybotrys spores are produced in slimy masses held together by a polysaccharide matrix — unlike dry-spored molds like Aspergillus or Penicillium, whose spores disperse freely into air. Multiple studies have failed to collect meaningful airborne Stachybotrys concentrations even in buildings with extensive visible black-mold growth (Brasel TL et al., Applied Environmental Microbiology 2005). Surface samples and bulk samples reliably detect Stachybotrys; air samples frequently do not. This is why air quality testing often underestimates Stachybotrys presence — and why visual inspection plus moisture assessment is the primary recommended evaluation method (both EPA and CDC recommend visual inspection, not air testing, as the first-line approach). Spores can become airborne when colonies dry out or are mechanically disturbed during demolition or remediation — which is why PPE is essential during cleanup.
EPA guidelines establish the following thresholds: Mold growth under 10 square feet can be handled by the homeowner with proper PPE — an N95 respirator, disposable gloves, and goggles. Mold growth above 10 square feet requires professional remediation. All remediation begins by stopping the water source — mold cannot persist or regrow without moisture. Porous materials that have absorbed mold (drywall, ceiling tiles, carpeting, insulation) should be removed and discarded — they cannot be effectively cleaned. Do not paint over moldy surfaces. HEPA vacuum the area after removal of contaminated materials. Maintain indoor humidity below 50% going forward. Patients with asthma or other lung conditions should not be present during remediation. Post-remediation, re-inspect for moisture sources and recurrence. EPA and CDC do not recommend routine air testing for mold — visual inspection plus moisture assessment is the evidence-supported evaluation approach.
Yes — ImmunoCAP m227 testing for Stachybotrys chartarum IgE is commercially available and can provide documentation of sensitization. This documentation may be useful in rental-property disputes (establishing that Stachybotrys exposure occurred and caused measurable IgE response), homeowner insurance claims, or workplace accommodation requests. The limitation is that a positive Stachybotrys IgE does not prove causation of specific symptoms — it demonstrates sensitization to the mold's proteins, and the causal link to specific health effects is not always clear given CDC and IOM's balanced position on Stachybotrys-specific disease. A board-certified allergist can provide documentation of the IgE result and its clinical interpretation in the context of your exposure history and symptom timeline.
After professional building remediation, the most clinically actionable allergy treatment path starts with testing for co-positive molds that do have SCIT evidence — Alternaria, Cladosporium, Aspergillus, and Penicillium. These molds frequently co-occur in water-damaged buildings alongside Stachybotrys, and any of them showing positive IgE in a patient with moderate-to-severe respiratory symptoms opens the door to SCIT. Alternaria has the strongest evidence (two DBPC-RCTs). For eligible patients, Curex offers at-home SCIT: a personalized serum sterile-compounded to USP <797> standards, self-administered as one weekly shot at home with pricing confirmed in a current program quote, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by your prescribing allergist. A large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots. Standard pharmacotherapy — antihistamines, nasal corticosteroids, leukotriene receptor antagonists, inhaled bronchodilators for asthma — manages ongoing symptoms and is the first-line treatment while awaiting remediation or after remediation when symptoms persist.
No — Stachybotrys chartarum requires water activity above 0.94 to grow, which corresponds to materials that have been thoroughly wetted by water intrusion, flooding, or sustained heavy condensation from a water leak. Normal bathroom humidity — even a steamy shower daily — does not create the sustained high-moisture condition Stachybotrys needs. The black mold found on shower grout, tile, and caulking is almost always Cladosporium or Aspergillus niger (both of which can colonize at lower water activity), not Stachybotrys. Stachybotrys is found on wet paper backing of drywall, wet ceiling tiles, water-soaked carpet padding, and wet wood — materials that have been saturated for extended periods. Its presence reliably indicates serious water damage, not ordinary bathroom moisture. If you see dark mold on your shower tile, it is almost certainly not Stachybotrys.
Stachybotrys IgE testing (ImmunoCAP m227) is most useful in specific clinical contexts: patients with documented water-damaged building exposure who have respiratory symptoms, documentation for insurance or legal remediation disputes, and comprehensive mold panels when unexplained IgE results require context. The key limitation: even a positive Stachybotrys IgE does not translate into an available immunotherapy. The practical value of the test is documentation and understanding sensitization patterns — a positive result in a patient who is also positive for Alternaria or Aspergillus helps confirm that water-damaged-building mold exposure is the driver and that those co-positive molds with SCIT options are relevant treatment targets. Testing Stachybotrys IgE alone without testing other molds provides incomplete clinical guidance.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.